SiMPLInext
Market acceptance of Consumers Goods and Chemicals and Pharma passes through mandatory tests on animals. However, physicians object that data obtained on different species are not valid for humans. The solution to this contradiction is the in vitro approach, namely starting with cells coming from the human body and to engineer living tissues. in vitro is well known for decades but remains “niche” because has been suffering the lack of appropriate qualification.
SiMPLInext SA’s ambition is to enable toxicologists to make in vitro, so far considered low-tech, high-tech, to foster its industrial adoption as required by Global Toxicology Services Markets in Pharma, Chemicals and Consumers Goods.
This can be achieved thanks to the proprietary CoMPLI-SiMPLI SSI® complementary digital platform, the first IoT complete solution for in vitro human tissue qualification. The focus is on in vitro models of lungs and intestine, which are keys for drug toxicity and efficacy.
CoMPLI-SiMPLI SSI® (Smart System Integrated®) is a complementary kit which includes three products: the single-use insert SiMPLI, the digital module CoMPLI, and the software MuLTIPLI. The system tracks the real-time changes in cell barrier function as well as cell attachment behavior.
The support of STI is essential to validate the of proof-of-concept and to pave the way to the product market fit validation phase.